Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: ghettogoulash who wrote (63186)	7/25/2025 8:29:44 PM
From: bodish	1 Recommendation Recommended By Olecranon Read Replies (1) of 63282

Thanks GG for posting this. What I found particularly interesting is that this mother discusses her 6 (or 7)-year-old son who was dosed with Elevidys in Dec 2024 and then after 7 or 8 weeks had elevated liver enzymes and was eventually hospitalized, and after increased steroids and IV steroids didn't work, was given Sirolimus and recovered completely. Sirolimus is the immunosuppressant with which Sarepta has proposed a protocol to submit to FDA for non-ambulatory patients who have liver issues after receiving Elevidys, but I had not seen any reports that it has already been used for patients who have received Elevidys treatment. I wonder if Stockdoc or another medical professional might weigh in on what the likelihood might be that other patients who have been treated with Elevidys might also have received Sirolimus, and what effect, if any, this one case might have on FDA either approving or rejecting Sarepta's proposed protocol to use Sirolimus for non-ambulatory patients who received Elevidys?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next